BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//pretalx//sciencenext.org//RJKNQ8
BEGIN:VTIMEZONE
TZID:EET
BEGIN:STANDARD
DTSTART:20001029T030000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20061029T000000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20071028T050000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10;UNTIL=20141026T020000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20151108T050000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=11;UNTIL=20151108T020000Z
TZNAME:EET
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
END:STANDARD
BEGIN:STANDARD
DTSTART:20160907T010000
RRULE:FREQ=YEARLY;BYDAY=1WE;BYMONTH=9
TZNAME:+03
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20000326T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20060326T000000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20070325T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20100328T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20110328T040000
RRULE:FREQ=YEARLY;BYDAY=4MO;BYMONTH=3;UNTIL=20110328T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20120325T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20130331T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20140331T040000
RRULE:FREQ=YEARLY;BYDAY=5MO;BYMONTH=3;UNTIL=20140331T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
BEGIN:DAYLIGHT
DTSTART:20150329T040000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3;UNTIL=20160327T020000Z
TZNAME:EEST
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:pretalx-ifos2026-RJKNQ8@sciencenext.org
DTSTART;TZID=EET:20260913T070000
DTEND;TZID=EET:20260913T073000
DESCRIPTION:<p style="margin-left: 0px!important\;">Over the past decade\, 
 immunological therapies have rapidly transformed the landscape of ENT medi
 cine\, with head and neck oncology leading the way. Immune checkpoint inhi
 bitors such as pembrolizumab and nivolumab have significantly extended sur
 vival in recurrent or metastatic head and neck squamous cell carcinoma (HN
 SCC)\, and novel combination strategies—including PD-1/LAG-3 or CTLA-4 b
 lockade—are showing promising results in neoadjuvant trials. Meanwhile\,
  chronic inflammatory ENT diseases like chronic rhinosinusitis with nasal 
 polyps (CRSwNP) are benefiting from a new wave of targeted biologics\, inc
 luding anti-IL-4/13 and anti-TSLP agents.</p><p style="margin-left: 0px!im
 portant\;">Despite these advances\, our field faces critical gaps. Biomark
 ers for treatment response remain under-validated\, the integration of imm
 unotherapy into standard ENT practice is uneven\, and ENT specialists risk
  falling behind without stronger engagement in immunological research. As 
 the role of immune mechanisms in ENT pathophysiology expands—from oncolo
 gy to allergy to autoimmunity—our specialty must work collaboratively ac
 ross disciplines to translate this momentum into more effective\, personal
 ized treatments. The potential for ENT-specific immunological research is 
 vast—and largely untapped. This session will explore how we can close th
 at gap.</p>
DTSTAMP:20260618T235019Z
LOCATION:Head & Neck Surgery 1
SUMMARY:Immunological Frontiers in ENT: Biologics\, Immuno-Oncology & Bioma
 rkers - Krzysztof Piersiala\, Tim Efthymios Kyrodimos
URL:https://sciencenext.org/ifos2026/talk/RJKNQ8/
END:VEVENT
END:VCALENDAR